Isolation and proliferation of umbilical cord tissue derived mesenchymal stem cells for clinical applications

被引:67
作者
Phuc Van Pham [1 ]
Nhat Chau Truong [1 ]
Phuong Thi-Bich Le [2 ]
Tung Dang-Xuan Tran [2 ]
Ngoc Bich Vu [1 ]
Khanh Hong-Thien Bui [3 ]
Ngoc Kim Phan [1 ]
机构
[1] Vietnam Natl Univ, Univ Sci, Lab Stem Cell Res & Applicat, Ho Chi Minh City, Vietnam
[2] Van Hanh Hosp, Van Hanh Stem Cell Unit, Ho Chi Minh City, Vietnam
[3] Univ Med & Pharm, Univ Med Ctr, Ho Chi Minh City, Vietnam
关键词
Activated platelet rich plasma; Clinical application of mesenchymal stem cells; Umbilical cord; Umbilical cord derived mesenchymal stem cells; Good manufacturing practice; UC-MSCs; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PLATELET-RICH PLASMA; FETAL BOVINE SERUM; TRAUMATIC BRAIN-INJURY; STROMAL CELLS; LIVER-FUNCTION; BONE-MARROW; BLOOD-SERUM; TRANSPLANTATION; EXPANSION;
D O I
10.1007/s10561-015-9541-6
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Umbilical cord (UC) is a rich source of rapidly proliferating mesenchymal stem cells (MSCs) that are easily cultured on a large-scale. Clinical applications of UC-MSCs include graft-versus-host disease, and diabetes mellitus types 1 and 2. UC-MSCs should be isolated and proliferated according to good manufacturing practice (GMP) with animal component-free medium, quality assurance, and quality control for their use in clinical applications. This study developed a GMP standard protocol for UC-MSC isolation and culture. UC blood and UC were collected from the same donors. Blood vasculature was removed from UC. UC blood was used as a source of activated platelet rich plasma (aPRP). Small fragments (1-2 mm(2)) of UC membrane and Wharton's jelly were cut and cultured in DMEM/F12 medium containing 1 % antibiotic-antimycotic, aPRP (2.5, 5, 7.5 and 10 %) at 37 A degrees C in 5 % CO2. The MSC properties of UC-MSCs at passage 5 such as osteoblast, chondroblast and adipocyte differentiation, and markers including CD13, CD14, CD29, CD34, CD44, CD45, CD73, CD90, CD105, and HLA-DR were confirmed. UC-MSCs also were analyzed for karyotype, expression of tumorigenesis related genes, cell cycle, doubling time as well as in vivo tumor formation in NOD/SCID mice. Control cells consisted of UC-MSCs cultured in DMEM/F12 plus 1 % antibiotic-antimycotic, and 10 % fetal bovine serum (FBS). All UC-MSC (n = 30) samples were successfully cultured in medium containing 7.5 and 10 % aPRP, 92 % of samples grew in 5.0 % aPRP, 86 % of samples in 2.5 % aPRP, and 72 % grew in 10 % FBS. UC-MSCs in these four groups exhibited similar marker profiles. Moreover, the proliferation rates in medium with PRP, especially 7.5 and 10 %, were significantly quicker compared with 2.5 and 5 % aPRP or 10 % FBS. These cells maintained a normal karyotype for 15 sub-cultures, and differentiated into osteoblasts, chondroblasts, and adipocytes. The analysis of pluripotent cell markers showed UC-MSCs maintained the expression of the oncogenes Nanog and Oct4 after long term culture but failed to transfer tumors in NOD/SCID mice. Replacing FBS with aPRP in the culture medium for UC tissues allowed the successful isolation of UC-MSCs that satisfy the minimum standards for clinical applications.
引用
收藏
页码:289 / 302
页数:14
相关论文
共 52 条
[1]   Osteogenic potential of human umbilical cord-derived mesenchymal stromal cells cultured with umbilical cord blood-derived fibrin: A preliminary study [J].
Baba, Kyoko ;
Yamazaki, Yasuharu ;
Ishiguro, Masashi ;
Kumazawa, Kenichi ;
Aoyagi, Kazuya ;
Ikemoto, Shigehiro ;
Takeda, Akira ;
Uchinuma, Eiju .
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2013, 41 (08) :775-782
[2]  
Badraiq Heba, 2015, Methods Mol Biol, V1283, P65, DOI 10.1007/7651_2014_116
[3]   Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow [J].
Bieback, Karen ;
Hecker, Andrea ;
Kocaoemer, Asli ;
Lannert, Heinrich ;
Schallmoser, Katharina ;
Strunk, Dirk ;
Klueter, Harald .
STEM CELLS, 2009, 27 (09) :2331-2341
[4]   Adipose tissue mesenchymal stem cell expansion in animal serum-free medium supplemented with autologous human platelet lysate [J].
Blande, Ivan Souza ;
Bassaneze, Vinicius ;
Lavini-Ramos, Carolina ;
Fae, Kellen Cristhina ;
Kalil, Jorge ;
Miyakawa, Ayumi Aurea ;
Schettert, Isolmar Tadeu ;
Krieger, Jose Eduardo .
TRANSFUSION, 2009, 49 (12) :2680-2685
[5]   Evaluation of a new standardized enzymatic isolation protocol for human umbilical cord-derived stem cells [J].
Buyl, Karolien ;
Vanhaecke, Tamara ;
Desmae, Terry ;
Lagneaux, Laurence ;
Rogiers, Vera ;
Najar, Mehdi ;
De Kock, Joery .
TOXICOLOGY IN VITRO, 2015, 29 (06) :1254-1262
[6]  
Chen Guang-hua, 2012, Zhonghua Xue Ye Xue Za Zhi, V33, P303
[7]   Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury [J].
Cheng, Hongbin ;
Liu, Xuebin ;
Hua, Rongrong ;
Dai, Guanghui ;
Wang, Xiaodong ;
Gao, Jianhua ;
An, Yihua .
JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
[8]   Human Umbilical Cord Mesenchymal Stem Cells: A New Era for Stem Cell Therapy [J].
Ding, Dah-Ching ;
Chang, Yu-Hsun ;
Shyu, Woei-Cherng ;
Lin, Shinn-Zong .
CELL TRANSPLANTATION, 2015, 24 (03) :339-347
[9]   Human umbilical cord-derived MSC culture: the replacement of animal sera with human cord blood plasma [J].
Ding, Yan ;
Yang, Hua ;
Feng, Jing Bo ;
Qiu, Ying ;
Li, Dong Sheng ;
Zeng, Yi .
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2013, 49 (10) :771-777
[10]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317